Patents Assigned to AstraZeneca
  • SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
    Publication number: 20090124578
    Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.
    Type: Application
    Filed: January 13, 2009
    Publication date: May 14, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Ian EGLE, Babu Joseph, Abdelmalik Slassi, Methvin Isaac, Fupeng Ma, Joshua Clayton
  • TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF
    Publication number: 20090123476
    Abstract: Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
    Type: Application
    Filed: April 9, 2007
    Publication date: May 14, 2009
    Applicant: AstraZeneca AB
    Inventors: Paul Elvin, Stephen Charles Emery, Qing Zhou
  • Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor
    Publication number: 20090124640
    Abstract: The present invention relates to a new compound A: [Chemical formula should be inserted here. Please see paper copy] a process for its preparation, pharmaceutical formulations containing said therapeutically active compound and to the use of said active compound in therapy. The compound is an inhibitor of the enzyme MPO and is thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.
    Type: Application
    Filed: June 4, 2007
    Publication date: May 14, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Anna-Karin Tiden, Cecilia Weistrand
  • Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794
    Publication number: 20090124637
    Abstract: There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, R4 and R5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.
    Type: Application
    Filed: April 3, 2006
    Publication date: May 14, 2009
    Applicant: AstraZeneca AB
    Inventors: Gunnar Nordvall, Colin Ray, Tobias Rein, Daniel Sohn
  • COMBINATION OF ANGIOPOIETIN-2 ANTAGONIST AND OF VEGF-A, KDR AND/OR FLTL ANTAGONIST FOR TREATING CANCER
    Publication number: 20090123474
    Abstract: The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists.
    Type: Application
    Filed: December 12, 2006
    Publication date: May 14, 2009
    Applicant: ASTRAZENECA AB
    Inventors: David Charles Blakey, Jeffrey Lester Brown, Stephen Charles Emery
  • Chemical Compounds
    Publication number: 20090118513
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Application
    Filed: January 15, 2009
    Publication date: May 7, 2009
    Applicant: AstraZeneca AB
    Inventors: Moya Caffrey, Christopher Luckhurst, Tobias Mochel, Matthew Perry, Brian Springthorpe
  • SUBSTITUTED ADENINES AND THE USES THEREOF
    Publication number: 20090118220
    Abstract: This invention relates to compounds of Formula I: and their use in the treatment of bacterial infections.
    Type: Application
    Filed: April 2, 2007
    Publication date: May 7, 2009
    Applicant: AstraZeneca AB
    Inventors: Marta Cavero-Tomas, Jenna Harang, Hoan Khai Huynh, Haihong Ni, Suzanne Stokes
  • Therapeutic Agents - 551
    Publication number: 20090118332
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof, processes for preparing such compounds, their use as Fatty Acid Synthase inhibitors, methods for their therapeutic use, particularly in the treatment of obesity, diabetes mellitus, cancer and infection and pharmaceutical compositions containing them.
    Type: Application
    Filed: December 20, 2007
    Publication date: May 7, 2009
    Applicant: AstraZeneca AB
    Inventors: Roger John Butlin, Peter William Rodney Caulkett, Andrew Leach, Nicholas John Newcombe, Charles John O'Donnell, James Matthew Wood
  • N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor
    Publication number: 20090118288
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.
    Type: Application
    Filed: July 19, 2006
    Publication date: May 7, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Christopher Luckhurst, Brian Springthorpe
  • QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS
    Publication number: 20090118261
    Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: August 26, 2005
    Publication date: May 7, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Leslie Dakin, Jayachandran Ezhuthachan, Stephen Lee, Paul Lyne, Timothy Pontz, XiaoLan Zheng
  • Novel Adenine Compound
    Publication number: 20090118263
    Abstract: An adenine compound represented by the formula (1): (1) [wherein A1 and A2 each independently represents an (un)substituted aromatic carbocycle or (un)substituted aromatic heterocycle; L1, L2, and L3 each independently represents alkylene or a single bond, provided that any methylene or methine group in L2 or L3 may be bonded to the nitrogen atom adjacent to L2 and L3 to form a 4- to 7-membered saturated nitrogenous heterocycle; L4 represents alkylene or a single bond; R1 represents (un)substituted alkyl, (un)substituted aryl, etc.; R2 represents hydrogen or (un)substituted alkyl; R3 represents (un)substituted alkyl, etc.; and X represents oxygen, etc.] or a pharmaceutically acceptable salt of the compound. The compound and salt are useful as a medicine.
    Type: Application
    Filed: September 20, 2006
    Publication date: May 7, 2009
    Applicants: Dainippon Sumitomo Pharma Co., Ltd., ASTRAZENECA AKTIEBOLAG
    Inventors: Kazuki Hashimoto, Tomoaki Nakamura, Kei Nakamura, Ayumu Kurimoto, Yoshiaki Isobe
  • PYRIDINE AND PYRAZINE DERIVATIVES - 083
    Publication number: 20090118305
    Abstract: The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: October 23, 2008
    Publication date: May 7, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe Barlaam, Craig Steven Harris, Christine Marie Paul Lambert, Gilles Ouvry, Justin Fairfield Bower, Benedicte Delouvrie, Gary Fairley, Jon James Gordon Winter
  • Phosphonooxy quinazoline derivatives and their pharmaceutical use
    Patent number: 7528121
    Abstract: Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: May 5, 2009
    Assignee: AstraZeneca AB
    Inventors: Nicola Murdoch Heron, Andrew Austen Mortlock
  • Compounds
    Patent number: 7528156
    Abstract: The invention provides compounds of general formula (D wherein m, n, Q, Z1, Z2, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: May 5, 2009
    Assignee: AstraZeneca AB
    Inventors: Tomas Eriksson, Tomas Klingstedt, Tesfaledet Mussie
  • 1,2,4-TRIAZOLE CARBOXYLIC ACID DERIVATIVES AS MODULATORS OF MGLUR5
    Publication number: 20090111811
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Kenneth GRANBERG, Abdelmalik Slassi, Tomislav Stefanac, Andreas Wallberg
  • 1,2,3-TRIAZOLE PYRROLIDINE DERIVATIVES AS MODULATORS OF MGLUR5
    Publication number: 20090111822
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Emma BRATT, Kenneth Granberg
  • 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5
    Publication number: 20090111857
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Peter DOVE, Kenneth Granberg, Methvin Isaac, Mats Nagard, Abdelmalik Slassi
  • Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof
    Publication number: 20090111865
    Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4 and Z are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: January 8, 2009
    Publication date: April 30, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Ziping Liu, Daniel Page, Christopher Walpole, Hua Yang
  • SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
    Publication number: 20090111830
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: February 15, 2006
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • AMINOPYRIDINE DERIVATIVES AS MODULATORS OF MGLUR5
    Publication number: 20090111823
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Kenneth GRANBERG, Bjorn Holm